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The basolateral nucleus (BLA) of the amygdala contributes to the consolidation of memories for emotional or stressful events. The nucleus 
contains a high density of CRF1 receptors that are activated by corticotropin-releasing factor (CRF). Modulation of the excitability of 
neurons in the BLA by CRF may regulate the immediate response to stressful events and the formation of associated memories. In the 
present study, CRF was found to increase the amplitude of ﬁ  eld potentials recorded in the BLA following excitatory afferent stimulation, 
in vitro. The increase was mediated by CRF1 receptors, since it could be blocked by the selective, non-peptide antagonists, NBI30775 
and NBI35583, but not by the CRF2-selective antagonist, astressin 2B. Furthermore, the CRF2-selective agonist, urocortin II had no 
effect on ﬁ  eld potential amplitude. The increase induced by CRF was long-lasting, could not be reversed by subsequent administration 
of NBI35583, and required the activation of protein kinase C. This effect of CRF in the BLA may be important for increasing the salience 
of aversive stimuli under stressful conditions, and for enhancing the consolidation of associated memories. The results provide further 
justiﬁ  cation for studying the efﬁ  cacy of selective antagonists of the CRF1 receptor to reduce memory formation linked to emotional or 
traumatic events, and suggest that these compounds might be useful as prophylactic treatments for stress-related illnesses such as 
post-traumatic stress disorder.
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INTRODUCTION
Corticotropin-releasing factor (CRF) is a 41-amino acid peptide 
released from neurons within the CNS that modulates neural 
activity through activation of CRF1 and CRF2 receptors present 
in discrete brain areas (Holmes et  al., 2003). The peptide is 
known to contribute to the behavioural and autonomic response 
to stress (Croiset et al., 2000; Koob and Henrichs, 1999; Liu et al., 
2004; Makino et al., 2002; Rainnie et al., 2004), in part through 
modulation of amygdala function. The amygdala plays a key role 
in the central processing of stressful or emotionally charged stim-
uli (Davis, 1992; Phelps and LeDoux, 2005), and in particular, 
the basolateral complex of the amygdala (BLA) has been shown 
to mediate emotional arousal (Roozendaal et al., 2002) and the 
consolidation of emotional memory (McGaugh, 2004; Paré, 
2003). The BLA receives excitatory input from diverse regions 
of the CNS, including the thalamus (Blair et al., 2003; Muller 
et al., 1997; Turner and Herkenham, 1991), lateral entorhinal 
cortex (Mcdonald and Mascagni, 1997), hippocampus, frontal 
cortex (Pitkanen et al., 1997), occipital cortex (Mcdonald and 
Mascagni, 1996), and temporal cortex (Mascagni et al., 1993), 
so is well placed to integrate sensory input with information 
already in memory. Repeated activation of the BLA, or repetitive 
administration of exogenous CRF receptor agonists results in 
altered sensitivity of BLA neurons to further stimulation, and the 
development of a chronic anxiety-like state (Sajdyk and Gehlert, 
2000). Activation of CRF receptors in the BLA has been shown 
to increase the excitability of projection neurons through the 
inhibition of a calcium-dependent potassium channel (Rainnie 
et al., 1992); an effect that was most likely mediated by CRF1 
receptors given their high density on these neurons (Chalmers 
et al., 1995; Chen et al., 2000; Van Pett et al., 2000). This effect 
of CRF on projection neurons in the BLA contrasted with 
the peptide’s action in the central amygdala, where it reduced the 
excitability of recorded cells. CRF has long been known to have 
excitatory effects on neurons in the CNS (Siggins et al., 1985), 
with notable effect on the ﬁ  ring of dopaminergic neurons in the 
ventral tegmental area (Korotkova et al., 2006). Of particular 
relevance to the current study, CRF has been shown to induce a 
long-lasting increase in the excitability of neurons in the dentate 
gyrus of the hippocampus, in vivo (Wang et al., 2000), an effect 
that was dependent on protein synthesis and suggests that the 
peptide may have profound effects on long-term neural func-
tion and plasticity.
Given the recent availability of selective CRF1 receptor lig-
ands, in particular the non-peptide CRF1 receptor antagonists, 
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NBI35583 (Guo et al., 2005) and NBI30775 (Chen and Grigoriadis, 
2005), we have now investigated the pharmacology of CRF modu-
lation of neural activity in the BLA following afferent stimulation, 
in vitro. These studies may help to understand how selective CRF1 
receptor antagonists might be of beneﬁ  t in the treatment of stress-
related disorders.
MATERIALS AND METHODS
All work was carried out in compliance with the Italian national 
legislation (DL 116/92) and European Directive 86/609.
SUBJECTS AND BRAIN SLICE PREPARATION
In vitro brain slices were obtained from male Sprague-Dawley 
rats (80–100 g; 3–4 weeks of age). Rats were anaesthetised with 
ether or isoﬂ  urane and decapitated. The brain was removed and 
cooled rapidly in a modiﬁ  ed artiﬁ  cial cerebrospinal ﬂ  uid (ACSF) 
solution (0–6°C) bubbled continuously with 95% O2 and 5% 
CO2 to maintain pH (7.35–7.45). Coronal slices (400 μm) were 
cut using a Vibroslice (Campden Instruments) and placed in 
oxygenated ACSF at 21°C. Following incubation for at least 1 h, 
a slice was transferred to the recording chamber, where it was 
fully submerged and continuously perfused with oxygenated 
ACSF maintained at 33 ± 1°C. ACSF was made up as follows 
(in mM): 118 NaCl, 3 KCl, 1 MgCl2, 1 NaH2PO4, 2.5 CaCl, 11 
D-glucose, and 25 NaHCO3.
ELECTROPHYSIOLOGICAL RECORDING
The basolateral complex of the amygdala, composed of the lat-
eral and basolateral nuclei was evident as the region deﬁ  ned on 
its lateral border by the external capsule and its medial border 
by the longitudinal association bundle. Extracellular ﬁ  eld poten-
tials were evoked by stimulation (0.05  Hz, 0.1  ms duration) 
delivered to the lateral nucleus with a bipolar electrode and 
recorded with a glass micropipette containing ACSF (resistance 
3–8 MΩ). Unless otherwise stated, the stimulus amplitude was set 
to produce a response that was ∼60–80% of the maximum ﬁ  eld 
potential amplitude at baseline. Field potentials were ampliﬁ  ed 
(Axoprobe-1A, Axon Instruments), bandpass ﬁ  ltered between 
3  Hz and 3  kHz and digitised using a National Instruments 
interface running custom Labview software. Data are expressed 
as mean ± SEM; n = number of slices (in some cases where mul-
tiple slices were derived from the same rat, the number of rats is 
also indicated in the ﬁ  gure legend). The effect of treatment on 
stimulus-response and paired-pulse results were analysed using 
a two-way ANOVA. All other data were analysed using paired 
or unpaired Student’s t-tests, or ANOVA followed by a post-hoc 
test, as indicated.
DRUGS
Drugs were dissolved in ACSF and introduced to the recording 
chamber at a ﬂ  ow rate of 2 ml/min. Human/rat CRF; the AMPA 
glutamate receptor antagonist, 6-Cyano-7-nitroquinoxaline-
2,3-dione (CNQX), the protein kinase A (PKA) inhibitor, N-
[2-(p-Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide 
dihydrochloride (H-89); the protein kinase C (PKC) inhibitor, 3-
(N-[Dimethylamino]propyl-3-indolyl)-4-(3-indolyl)maleimide 
(BIS-I) were all obtained from Sigma-Aldrich (St. Louis, MO, 
USA). The selective CRF1 receptor antagonists NB30775, NBI 
35583; the selective CRF2 receptor agonist, urocortin II, and 
antagonist, astressin 2B, were gifts from Neurocrine Inc. and the 
Salk Institute (USA).
RESULTS
EVOKED FIELD RESPONSES IN THE BASOLATERAL AMYGDALA
Stimulation of the lateral amygdala evoked a characteristic 
ﬁ  eld potential in the BLA. The ﬁ  eld potentials were composed 
of a short latency (1 ms) negative-going potential, which was 
unaffected by CNQX (Figure 1A), but which was inhibited 
by TTX (100 nM, Figure 1B). This was followed by a second, 
longer latency (2–3  ms) negative going potential that could 
be inhibited by application of the AMPA/kainate receptor 
antagonist, CNQX (10 μM, n = 6, Figure 1A), as well as by TTX 
(Figure 1B).
EFFECT OF CRF
Application of CRF (0.1 μM) to the slice signiﬁ  cantly enhanced 
the amplitude of the longer latency synaptic response (fPSP), 
but not the early response (Figure 2).
Furthermore, the enhancement was sustained beyond the 
washout of the peptide (Figure 3A). In order to deﬁ  ne more 
clearly the component of the ﬁ  eld response that was affected 
by CRF, a series of experiments was conducted in which TTX 
was applied at the end of the experiment and the residual non-
biological component digitally subtracted from the responses 
(Figure 3B). In this series, CRF (0.1  μM) again produced a 
signiﬁ  cant increase in the amplitude of the fPSP component 
(44 ± 11%; p < 0.01, paired t-test, n = 7 slices, Figure 3C).
The increase in fPSP produced by CRF was apparent over 
a range of stimulus intensities (repeated measures two-way 
ANOVA: signiﬁ  cant effect of current, F(5,36) = 13, p < 0.0001; 
signiﬁ  cant effect of CRF, F(1,36) = 29, p < 0.0001; no interaction 
between current and CRF, F(5,36) = 1.8, p = 0.14; n = 7 slices); 
although a post-hoc Bonferroni test showed that a   signiﬁ  cant 
Figure 1 | Example ﬁ  eld potentials evoked in the BLA by stimulation of 
the lateral amygdala. (A) ±CNQX (10 μM); (B) ±TTX (100 nM). In each case, 
the black trace = baseline, grey trace = after drug; horizontal scale bars 2 ms, 
vertical 0.2 mV.
B A
Figure 2 | The averaged ﬁ  eld potential (n = 20 responses) before and after 
application of CRF (0.1 μM). The black trace = baseline, grey trace = after 
drug; horizontal scale bars 2 ms, vertical 0.2 mV.www.frontiersin.org
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increase occurred only at the highest stimulus intensities 
(Figure 3D). In order to determine whether the effect of CRF 
was likely to be due to a pre- or post-synaptic action, responses 
to pairs of stimuli separated by a short interval were examined. 
CRF (0.1 μM) had no effect on the paired-pulse proﬁ  le obtained 
with inter-pulse intervals of 20–200  ms (repeated measures 
two-way ANOVA: signiﬁ  cant effect of interval, F(6,49) = 3.0, 
p < 0.05; no effect of CRF, F(1,49) = 1.96, p = 0.17, no interac-
tion between interval and CRF, F(6,49) = 0.51, p = 0.79; n = 8 
slices, Figure 3E).
Figure 3 | (A) Timecourse of fPSP amplitude and example traces (i) at baseline, (ii) following application of CRF (0.1 μM), (iii) following washout of the CRF and 
application of CNQX (10 μM), and (iv) following application of TTX (100 nM). Each symbol represents the fPSP amplitude for a single response. Horizontal scale 
bar 10 min. (B) Example of evoked ﬁ  eld potentials before (black trace) and after (grey trace) the application of CRF (0.1 μM); the non-biological component that 
was not sensitive to TTX applied at the end of the experiment has been digitally removed. Dotted lines indicate the method for determining the fPSP amplitude. 
(C) The mean fPSP amplitude evoked by currents at 60–80% of maximum at baseline and after 15 min incubation with CRF (0.1 μM). Amplitude was determined 
from responses similar to that shown in (B). **p < 0.01, paired t-test, n = 7 slices, 5 rats. (D) Stimulus current-response relationship for evoked fPSPs in the 
absence (z) and presence ({) of CRF (0.1 μM), statistical analysis was carried using a two-way repeated measures ANOVA (see text) followed by a post-hoc 
Bonferroni test (*p < 0.05, **p < 0.01, n = 7 slices, 5 rats). (E) Paired-pulse relationship for evoked fPSPs in the absence (z) and presence ({) or CRF (0.1 μM), 
statistical analysis was carried out using a two-way repeated-measures ANOVA (see text; n = 8 slices, 5 rats).
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DETERMINATION OF THE RECEPTOR MEDIATING THE EFFECT OF CRF
The CRF1 selective antagonist, NBI35583 signiﬁ  cantly reduced 
the enhancement of fPSP amplitude induced by 0.1  μM 
CRF in a concentration-dependent manner, with a pIC50 of 
6.7 ± 0.2 (data ﬁ  tted to a sigmoidal curve of the form Y = min + 
{max − min  [1 + 10^(LogIC50-X)]};  n =  6–12 slices per con-
centration;  Figure 4A). A second CRF1 selective antagonist, 
NBI30775 tested at a single concentration of 1 μM also signiﬁ  -
cantly reduced the response to the peptide (CRF alone: 33 ± 6% 
increase, CRF + NBI 30775: 11 ± 4% increase, p < 0.05 unpaired 
t-test, n = 6–9 slices; Figure 4B).
In further experiments, a selective CRF2 receptor agonist, 
urocortin II (0.1  μM; functional cAMP accumulation driven 
by mouse recombinant CRF2, EC50 = 0.14 nM, and by human 
recombinant CRF1, EC50 > 100 nM; Reyes et al., 2001) had no 
effect on fPSP amplitude alone (2 ± 4% increase, p > 0.05, paired 
t-test, n = 6 slices), while on the same slices, subsequent applica-
tion of CRF (0.1 μM) enhanced fPSP amplitude (Figure 5A). 
Finally, the CRF2 receptor-selective antagonist, astressin 2B 
(0.1 μM; binding afﬁ  nity for human recombinant CRF2 recep-
tors, IC50 = 1.3 nM,  and  hCRF1  IC50 > 500 nM;  Rivier  et al., 
2002), applied 20 min before CRF, failed to block the effect of 
the latter on fPSP amplitude (CRF alone: 25  ± 4%  increase, 
n = 3; CRF + astressin 2B: 29 ± 7% increase, n = 8 slices, p > 0.05 
unpaired t-test; Figure 5B).
DETERMINATION OF THE DOWNSTREAM CONSEQUENCE OF 
CRF RECEPTOR ACTIVATION
The enhancement of evoked fPSPs by CRF (0.1  μM) above 
  baseline remained signiﬁ  cant 30 min after wash-out of the pep-
tide (15 min treatment with CRF: 55 ± 12% increase over base-
line,  p < 0.001,  n =  7 slices; 30  min after washout: 41  ± 11% 
increase over baseline, p < 0.01,  n =  7 slices; one-way repeated 
measures ANOVA followed by Bonferroni test; Figure 6). 
Furthermore, from this same analysis, the increase 30 min after 
washout was not signiﬁ  cantly different to that at the end of the 
15-min incubation with CRF. In a separate series of experiments, 
the antagonist, NBI35583 (1 μM) was added to the superfusion 
during the washout of CRF; however, again the fPSP remained 
signiﬁ  cantly elevated after 30 min of washout (15 min treatment 
with CRF: 50 ± 12%, p < 0.01, n = 6 slices; 30 min of washout in 
the presence of 1 μM NBI 35583: 37 ± 7%, p < 0.05, n = 6 slices; 
one-way repeated measures ANOVA followed by Bonferroni test; 
Figure 6). From this analysis, the increase 30 min after washout in 
the presence of NBI35583 was not signiﬁ  cantly different to that at 
the end of the 15-min incubation with CRF.
In order to investigate the downstream intracellular pathways 
activated by CRF, the effects of the peptide were examined on 
slices pre-treated for 1 h with the selective PKA inhibitor H-89 
or the selective PKC inhibitor BIS-I. As a control, CRF (0.1 μM) 
was applied to separate slices that had been obtained from the 
Figure 4 | (A) The CRF1 receptor antagonists NBI 35583 (0.1–1.0 μM, 20 min before 0.1 μM CRF); data shown are the mean ± SEM from 12 control slices 
(11 rats) and 6–9 slices (3–6 rats) pretreated with antagonist at the concentrations indicated. *p < 0.05, ***p < 0.001, one-way ANOVA followed by Bonferroni 
t-test. (B) NBI 30775 (1 μM, 20 min before CRF) blocked the increase in fPSP amplitude induced by 0.1 μM CRF; data shown are the mean ± SEM from 9 control 
slices (7 rats) and 6 slices (6 rats) pretreated with the antagonist. *p < 0.05, unpaired t-test.
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same rat, but which had not been exposed to the inhibitors. 
The enhancement of the fPSP by CRF in the presence of H-89 
(10 μM) was similar to that in control slices (control: 33 ± 10% 
vs. H-89-treated: 28 ± 6%, n = 7 slices per group; Figure 6); fur-
thermore, H-89 did not affect the longevity of the increase 30 min 
after washout of CRF (control: 31 ± 11%; H-89: 29 ± 6%, n = 7 
slices; Figure 7). However, in the presence of BIS-I (1.2 μM), 
the enhancement by CRF was signiﬁ  cantly reduced both dur-
ing application of the peptide (control: 35 ± 5%, BIS-I: 8 ± 3%, 
p < 0.05, one-way ANOVA followed by a Bonferroni test, n = 7 
slices per group; Figure 6) and 30 min after washout (control: 
47 ± 7%; BIS-I: 9 ± 3%, p < 0.001, one-way ANOVA followed by 
a Bonferroni test, n = 7 slices; Figure 7).
DISCUSSION
This study examined the effects of rat/human CRF peptide on 
ﬁ  eld potentials recorded in the BLA that were evoked by electrical 
stimulation within the lateral amygdala. The principal ﬁ  ndings 
were: (1) CRF increased the amplitude of the presumed post-
synaptic component of the ﬁ  eld potential via activation of CRF1 
receptors. (2) The increase due to CRF was maintained following 
washout of the peptide. (3) The increase was dependent on acti-
vation of PKC, but not PKA. These results suggest that activation 
of CRF1 receptors on neurons in the BLA leads to a long-  lasting 
increase in their response to afferent excitatory transmission. 
These ﬁ  ndings are discussed below.
Extracellular ﬁ  eld potential recording was used to evaluate 
drug effects on the response of BLA neurons to afferent excita-
tory stimulation. The ﬁ  eld potential responses observed in this 
study have been described by others (Aroniadou-Anderjaska 
et al., 2001; Chapman and Bellavance, 1992; Isoardi et al., 2004) 
and are suggested to reﬂ  ect two major physiological compo-
nents. The ﬁ  rst, a short latency negative-going potential, was 
unaffected by CNQX or CRF, but was abolished by TTX, con-
sistent with the suggestion that it reﬂ  ects the pre-synaptic ﬁ  bre 
volley (Isoardi et al., 2004). The second, longer latency, negative-
going component was inhibited by the AMPA/kainate glutamate 
receptor antagonist, CNQX, and is presumed to reﬂ  ect the excita-
tory post-synaptic response of neurons in the BLA (Isoardi et al., 
2004). This component was enhanced by CRF. Across several 
series of experiments described in the present study, the mean 
increase in the amplitude of the fPSP following application of 
CRF ranged from 25% (e.g. Figure 4B, n = 8) to nearly 60% (e.g. 
Figure 5, n = 7). This variation was also reﬂ  ected within experi-
ments such that the increase in fPSP amplitude due to CRF 
observed from individual BLA slices ranged from just 14–100%. 
In a subsequent study (manuscript in preparation), we found 
that the increase in fPSP following application of CRF was sig-
niﬁ  cantly reduced in brain slices obtained from rats previously 
exposed to behavioural stress, and furthermore was correlated 
with the trait anxiety level of the rat (determined from the ani-
mal’s behaviour on an elevated plus maze). Consequently, we 
suggest that different levels of stress in the groups of rats used 
in the present study and individual differences in trait anxiety 
might contribute to the range of increases observed with CRF 
in the present study. However, given the relatively small fPSP 
observed in the BLA in vitro, compared to more laminar struc-
tures such as the hippocampus, it is possible that methodologi-
cal variations also contribute to the apparent variation in CRF 
effect across experiments.
The use of selective CRF1 or CRF2 receptor ligands con-
ﬁ  rmed that the enhancement of evoked fPSPs by CRF was 
mediated by CRF1, and not CRF2 receptors since the effects 
could be blocked by the non-peptide CRF1-selective antago-
nists, NBI30775 and NBI35583, but not by the selective CRF2 
receptor peptide antagonist, astressin 2B. Furthermore, the pep-
tide agonist, urocortin II had no effect on fPSP amplitude. The 
pIC50 determined for NBI35583 in the present study is similar to 
that determined from the inhibition of CRF-stimulated ACTH 
 production by primary rat pituitary cells (pIC50 6.8 ± 0.3, n = 6; 
D. Grigoriadis, personal communication). These results are also 
consistent with the high density of CRF1 receptor mRNA and 
protein found in the BLA of the rat (Chalmers et al., 1995; Van 
Pett et al., 2000) and mouse (Chen et al., 2000). The enhance-
ment of fPSPs by CRF could arise through increased glutamate 
release or a change in the excitability of post-synaptic neurons. 
The absence of effect of CRF on the paired-pulse relationship 
is indicative of a post-synaptic effect, since enhanced glutamate 
release would be expected to affect the ratio of the amplitude 
Figure 6 | Comparison of the increase in fPSP amplitude following appli-
cation of CRF (0.1 μM) and 30 min after wash-out of the peptide in the 
absence (n = 7 slices from 5 rats) or presence of NBI35583 (1 μM; n = 6 
slices from 5 rats). Data shown are the mean ± SEM; *p < 0.05, **p < 0.01, 
***p < 0.001, N.S. not signiﬁ  cant, one-way repeated measures ANOVA fol-
lowed by Bonferroni multiple comparison.
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of the second fPSP relative to the ﬁ  rst in paired-pulse experi-
ments (Sanchez-Prieto et al., 1996). A drawback of ﬁ  eld poten-
tial recording used in the present study is the complexity of the 
ﬁ  eld response in the amygdala and the relatively small range of 
stimulation currents over which the response can be reliably 
measured. Consequently, we cannot rule out the possibility that 
the experiments were not sufﬁ  ciently sensitive to detect modu-
lation of the paired-pulse proﬁ  le by CRF. It remains possible 
that CRF1 receptors are expressed on the terminals of gluta-
matergic afferents into the BLA, since CRF1 receptor mRNA is 
observed in the lateral amygdala and other structures afferent 
to the BLA, such as the hippocampus, entorhinal cortex, and 
thalamus (Van Pett et al., 2000). Furthermore, CRF has been 
shown to enhance glutamate release in the rat locus coeru-
leus, in vivo (Singewald et al., 1996). However, a study of the 
potentiating effect of CRF on afferent excitation in the lateral 
septum also showed that the peptide had no effect on paired-
pulse facilitation, leading the authors to suggest a post-synaptic 
site of action (Liu et al., 2004). This latter study investigated 
the effects of CRF on the response of individual neurons in the 
lateral septum, so is likely to have been more sensitive to effects 
on paired-pulse facilitation.
The enhancement of evoked fPSPs by CRF was maintained 
following washout of the peptide, and could not be reversed by 
application of the antagonist, NBI35583 during washout. A pos-
sible explanation for this observation might be slow kinetics of 
dissociation of the peptide from CRF receptors in the slice, such 
that application of the competitive antagonist was insufﬁ  cient 
to displace CRF from the receptors during the 30-min washout. 
However, given the high concentration of NBI35583 used in these 
experiments, this explanation seems unlikely. Alternatively, CRF1 
receptor activation may couple to a downstream effector that, 
once activated, is then independent of CRF receptor stimulation. 
A similarly prolonged effect of CRF in the BLA was reported by 
Rainnie et al. (1992), discussed further below. Whilst we have 
yet to identify the ﬁ  nal effector mechanism responsible for the 
enhancement of fPSPs by CRF, it is likely to be downstream of 
PKC, since the effects of CRF could be prevented by prior applica-
tion of the PKC inhibitor BIS-I, but not the PKA inhibitor H-89. 
Concentrations of the two inhibitors selective for PKC and PKA 
were chosen based on studies by Blank et al. (2003). CRF1 recep-
tors have previously been reported to couple to both Gs and Gq 
G-proteins to activate PKA and PKC, respectively in the mouse 
hippocampus (Blank et al., 2003; Eckart et al., 2002). The modu-
lation by CRF of serotonergic regulation of GABAergic transmis-
sion in prefrontal cortex has been shown to be mediated by CRF1 
receptors coupled through PKC (Tan et al., 2004). Furthermore, 
CRF-induced inhibition of   adenylate cyclase is mediated by PKC 
in rat Leydig cells (Ulisse et al., 1990).
Rainnie et al. (1992), using current clamp recording from 
neurons in the BLA, found that CRF (0.125 μM) reduced the 
slow after-hyperpolarisation (s-AHP) following action potentials 
evoked by current injection. The peptide also increased calcium 
spikes recorded in the presence of TTX and TEA, a voltage-gated 
potassium channel blocker. They did not determine whether 
these effects were mediated through activation of PKC, although 
they comment that a possible mechanism for the enhancement 
of calcium spikes by CRF might be the enhancement of calcium 
channel conductance, an effect that has been shown to be medi-
ated by both PKC and PKA in mouse anterior pituitary tumour 
cells (Reisine and Guild, 1987), and which was subsequently 
conﬁ  rmed to occur also in the central nucleus of the amygdala 
(Yu and Shinnick-Gallagher, 1998). The results of the study by 
Rainnie et al. (1992) demonstrate a clear post-synaptic effect of 
CRF on neurons in the BLA at a concentration similar to that 
used in the present study; furthermore, the observed reduction 
in s-AHP and enhanced calcium spikes are consistent with the 
enhanced ﬁ  eld potential response observed in the present study. 
Further studies combining intracellular recording from neurons 
in the BLA with afferent stimulation, similar to that conducted 
in the lateral septum by Liu et al. (2004), would be valuable to 
explore the mechanism underlying the enhancement of fPSPs in 
the present study.
The present results are reminiscent of the long-lasting 
increase in the excitability of neurons in the dentate gyrus of the 
hippocampus observed in vivo (Wang et al., 2000). In that earlier 
study, the identity of the CRF receptor mediating the effects was 
not determined; however, the increase in evoked ﬁ  eld responses 
was similar to that observed with electrically-induced long-term 
potentiation. The present results suggest that CRF-induced 
long-term plasticity may be a feature of several corticolimbic 
brain areas and thus may be an important regulator of learning 
and memory. Plasticity within the BLA is hypothesised to con-
tribute to the development of anxiety-related disorders (Rainnie 
et al., 2004; Shekhar et al., 2005). Studies in vivo have shown that 
repeated stimulation of the BLA or local injection of a CRF1 
agonist, urocortin, results in altered sensitivity of BLA neurons 
to further stimulation, the development of a chronic anxiety-like 
state (Sajdyk and Gehlert, 2000), and the facilitation of inhibi-
tory avoidance learning (Liang and Lee, 1988). Antagonists of 
the CRF1 receptor have been shown to inhibit aversive memory 
consolidation (Roozendaal et al., 2002), a process known to be 
dependent on BLA activity (McGaugh, 2004; Paré, 2003). For 
example, the CRF1 antagonist DMP696 has been shown to have 
no effect on the acquisition of contextual fear conditioning, but-
could prevent the expression of conditioning (freezing) when 
the animals were tested 48 h later, suggesting reduced consoli-
dation (Hubbard et al., 2007). This has led to the hypothesis that 
the release of stress hormones, such as CRF, in the amygdala is a 
critical mechanism by which stressful or aversive memories are 
reinforced (Roozendaal et al., 2008). The results of the present 
study provide further support for this hypothesis by providing 
evidence for a long-lasting enhancement of the responsivity of 
BLA neurons to afferent activation that is induced by CRF and 
mediated by CRF1 receptors. Thus, the acute release of CRF in 
the amygdala might contribute not only to increased anxiety in 
response to an aversive stimulus, but also a stronger consolida-
tion of memory for that stimulus and its context. Conﬁ  rmation 
in the present study that the effects of the CRF peptide in the 
BLA are mediated by CRF1 receptors contributes to the rationale 
to explore the therapeutic efﬁ  cacy of CRF1 receptor antagonists 
in patients suffering from stress-related disorders. In particu-
lar, the results suggest that CRF1 receptor antagonists might be 
 beneﬁ  cial in the prophylactic treatment of illnesses such as post-
traumatic stress disorder.
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